Sanofi’s Board of Directors has announced its intentions for the upcoming General Shareholder Meeting on April 30, 2024. The board proposes the renewal of Rachel Duan and Lise Kingo’s terms, alongside the appointment of Clotilde Delbos, Anne-Françoise Nesmes, and John…
AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics have unveiled a significant collaboration aimed at pioneering the development of conditionally-active, multi-specific biologics targeting oncology and immunology. This strategic alliance will harness AbbVie’s extensive experience in these fields alongside Tentarix’s groundbreaking Tentacles™…
Diakonos Oncology Corp. (“Diakonos”), a company in the clinical stage of immuno-oncology, has announced today the appointment of Dr. Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years of experience in the biotech and pharmaceutical industries, to its…
Leading global pharmaceutical company Lupin Limited (Lupin) has announced its receipt of approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for MinzoyaTM (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate…
EffRx Pharmaceuticals SA, a pharmaceutical company specializing in musculoskeletal and rare diseases medications, has disclosed the signing of an exclusive licensing and distribution arrangement for Binosto® in Vietnam and the Philippines with Lupin Limited (Lupin), a prominent global pharmaceutical company.…
Ono Pharmaceutical Co., Ltd. (Osaka, Japan), led by President and CEO Gyo Sagara, has announced a significant milestone today. The company has formalized an option and collaboration agreement with Numab Therapeutics AG (Horgen, Switzerland), under the leadership of CEO David…
Today, GSK has announced the successful completion of its acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously announced, this acquisition includes AIO-001, a…
Takeda (TSE:4502/NYSE:TAK) has unveiled positive topline findings from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial assessing TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients diagnosed with narcolepsy type 1. Narcolepsy, a chronic and rare neurological disorder…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has revealed that the anti-CD20/CD3 bispecific antibody mosunetuzumab has successfully met the primary endpoint of achieving a complete response rate (CRR) in an expansion cohort within the Japanese Phase I study. This study aimed…
Novartis has announced its intent to initiate a voluntary public takeover offer for the acquisition of MorphoSys AG (FSE: MOR; NASDAQ: MOR), a global biopharmaceutical company headquartered in Germany, specializing in innovative oncology medicines. The proposed acquisition, contingent upon customary…
Merck Animal Health, operating as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), headquartered in Rahway, N.J., USA, has officially entered into a definitive agreement to acquire Elanco Animal Health…
Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known as “TAPI.” A prominent player in the global small-molecule API…